ERBB2 and neoplasm: Bispecific antibody targeting both PD‐1 and Her2 could crosslink Her2‐positive tumor cells with T cells to form PD‐1 immune synapses to guide the killing of tumor cells without antigen recognition.[11, 12, 13, 14, 15] We observed that IBI315 could kill target cells to a large extent in the tumor cells or organoid/T cells coculture system, whereas the killing effect was not observed in the parental mAbs or parental two‐drug combination groups.